Repurposing Public 23Q2

This data release contains the most recent PRISM Repurposing screens: Repurposing-1M. All Repurposing-1M [REP1M] compounds (1280 REP1M) were screened in the PRISM assay at a dose of 2.5 μM with a 5-day treatment against 906 cancer cell lines (859 of them passed quality checks -QC- for all tested compound with two high quality replicates). Two PRISM cell line collections were used in the assay: PR500A, which includes only adherent cell lines, and PR500B, which has adherent and suspension cell lines. Together, these PRISM cell line collections form the PR1000 cell line collection. All compounds were run in triplicate, and each plate contained positive (Bortezomib, 20μM) and negative (DMSO) controls. The screen can be considered an extension of the PRISM Repurposing Primary Screen, with PR500A mainly covering the existing cell line panel, while PR500B extends the cell line collection with new subtypes and lineages. For the assay details, please refer to Corsello et al., 2020 (doi.org/10.1038/s43018-019-0018-6) and https://www.theprismlab.org.